Citation: Qing Nian, Jinhao Zeng, Li He, Yu Chen, Zhiqiang Zhang, Fernando Rodrigues-Lima, Liyun Zhao, Xuanlin Feng, Jianyou Shi. A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma[J]. Chinese Chemical Letters, ;2021, 32(5): 1645-1652. doi: 10.1016/j.cclet.2021.01.002 shu

A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma

Qing Nian ^{a, 1} ,
Jinhao Zeng ^{a, 1} ,
Li He ^{e, 1} ,
Yu Chen ^b ,
Zhiqiang Zhang ^c ,
Fernando Rodrigues-Lima ^d ,
Liyun Zhao ^{e, *,} ,
Xuanlin Feng ^{f, *,} ,
Jianyou Shi ^{e, *,}

a.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China
b.
School of Clinical Medicine, Chengdu University of TCM, Chengdu 610072, China
c.
Department of Emergency, Binzhou Medical University Hospital, Binzhou 256603, China
d.
Unité de Biologie Fonctionnelle et Adaptative, Université de Paris, Paris 75013, France
e.
Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China
f.
Department of EICU, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu 610072, China

565340321@qq.com

23376592@qq.com

shijianyoude@126.com

Received Date: 7 November 2020
Revised Date: 5 December 2020
Accepted Date: 4 January 2021
Available Online: 8 January 2021

Figures(4)

The RAS/mitogen-activated protein kinase (MAPK) pathway disorder induced by the missense mutations in the tyrosine-protein phosphatase non-receptor type 11 (PTPN11) gene which resulted in the non-receptor protein tyrosine phosphatase SHP2 dysfunction has been reported in many lung cancer cases. Moreover, the Src homology region 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2) mutation or deletion triggers multiple signaling pathway dysfunctions including RAS/MAPK, RAS/extracellular-signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT), Janus kinase/signal transducers and activators of transcription (JAK/STAT) and Hippo/yes-associated protein (YAP) which affect the expression of growth factors, cytokines and hormones. In recent years, the developing of the small molecule SHP2 inhibitors received a lot of attention. In this review, we summarize the recent years' progresses of the SHP2 inhibitors development for the lung cancer treatment.
- Lung carcinoma,
- Small molecule inhibitor,
- SHP2,
- Targeted therapy,
- Gene mutation
1. [1]
  C. Zappa, S.A. Mousa, Transl. Lung Cancer Res. 5(2016) 288-300. doi: 10.21037/tlcr.2016.06.07
2. [2]
  N. Yasui, G.M. Findlay, G.D. Gish, et al., Mol. Cell 54(2014) 1034-1041. doi: 10.1016/j.molcel.2014.05.002
3. [3]
  M. Kim, M. Baek, D.J. Kim, Curr. Pharm. Des. 23(2017) 4226-4246.
4. [4]
  V.E. Schneeberger, N. Luetteke, Y. Ren, et al., Carcinogenesis 35(2014) 1717-1725. doi: 10.1093/carcin/bgu025
5. [5]
  L. He, Y. Li, X. Huang, H. Cheng, Y. Ke, et al., OncoTargets Ther. 12(2019) 5897-5906. doi: 10.2147/OTT.S210223
6. [6]
  L. Jiang, W. Xu, Y. Chen, Y. Zhang, Artif. Cells Nanomed. Biotechnol. 47(2019) 3231-3238. doi: 10.1080/21691401.2019.1646748
7. [7]
  S. Mainardi, A. Mulero-Sánchez, A. Prahallad, et al., Nat. Med. 7(2018) 961-967.
8. [8]
  A. Saiardi, R. Bhandari, A.C. Resnick, A.M. Snowman, S.H. Snyder, Science 5704(2004) 2101-2105.
9. [9]
  Y. Shi, Cell 139(2009) 468-484. doi: 10.1016/j.cell.2009.10.006
10. [10]
  A. Alonso, J. Sasin, N. Bottini, et al., Cell 117(2004) 699-711. doi: 10.1016/j.cell.2004.05.018
11. [11]
  E.N. Gurzov, W.J. Stanley, T.C. Brodnicki, H.E. Thomas, Trends Endocrinol. Metab. 26(2015) 30-39. doi: 10.1016/j.tem.2014.10.004
12. [12]
  L.I. Pao, K. Badour, K.A. Siminovitch, B.G. Neel, Annu. Rev. Immunol. 25(2007) 473-523. doi: 10.1146/annurev.immunol.23.021704.115647
13. [13]
  R.H. Reddy, H. Kim, S. Cha, B. Lee, Y.J. Kim, J. Microbiol. Biotechnol. 27(2017) 878-895. doi: 10.4014/jmb.1701.01079
14. [14]
  L. Li, X. Xu, Y. Du, et al., Toxicol. Appl. Pharmacol. 399(2020) 115053. doi: 10.1016/j.taap.2020.115053
15. [15]
  Y.M. Agazie, M.J. Hayman, Mol. Cell. Biol. 23(2003) 7875-7886. doi: 10.1128/MCB.23.21.7875-7886.2003
16. [16]
  J. Zhang, F. Zhang, R. Niu, J. Cell. Mol. Med. 19(2015) 2075-2083. doi: 10.1111/jcmm.12618
17. [17]
  T.J. Bauler, N. Kamiya, P.E. Lapinski, et al., Dis. Model. Mech. 4(2011) 228-239. doi: 10.1242/dmm.006130
18. [18]
  M. You, D.H. Yu, G.S. Feng, Mol. Cell. Biol. 19(1999) 2416-2424. doi: 10.1128/MCB.19.3.2416
19. [19]
  Z. Liu, Y. Zhao, J. Fang, et al., Oncotarget 8(2017) 53518-53530. doi: 10.18632/oncotarget.18591
20. [20]
  Y.J. Sun, Z.L. Zhuo, H.P. Xian, et al., Oncotarget 8(2017) 91123-91133. doi: 10.18632/oncotarget.20249
21. [21]
  M. Zhao, W. Guo, Y. Wu, et al., Acta Pharm. Sin. B 9(2019) 304-315. doi: 10.1016/j.apsb.2018.08.009
22. [22]
  Z.Y. Zhang, Curr. Opin. Chem. Biol. 5(2001) 416-423. doi: 10.1016/S1367-5931(00)00223-4
23. [23]
  P. Hof, S. Pluskey, S. Dhe-Paganon, M.J. Eck, S.E. Shoelson, Cell 92(1998) 441-450. doi: 10.1016/S0092-8674(00)80938-1
24. [24]
  E. Darian, O. Guvench, B. Yu, et al., Proteins 79(2011) 1573-1588. doi: 10.1002/prot.22984
25. [25]
  L. Chen, S.S. Sung, M.L. Yip, et al., Mol. Pharmacol. 70(2006) 562-570. doi: 10.1124/mol.106.025536
26. [26]
  R.A. Cerulli, J.A. Kritzer, Org. Biomol. Chem. 18(2020) 583-605. doi: 10.1039/C9OB01998G
27. [27]
  F.I. Nollmann, D.A. Ruess, Biomedicines 8(2020) 281. doi: 10.3390/biomedicines8080281
28. [28]
  X. Yuan, H. Bu, J. Zhou, C.Y. Yang, H. Zhang, J. Med. Chem. 63(2020) 11368-11396. doi: 10.1021/acs.jmedchem.0c00249
29. [29]
  T.A. Ahmed, C. Adamopoulos, Z. Karoulia, et al., Cell Rep. 26(2019) 65-78. doi: 10.1016/j.celrep.2018.12.013
30. [30]
  J.G. Fortanet, C.H. Chen, Y.N. Chen, et al., J. Med. Chem. 59(2016) 7773-7782. doi: 10.1021/acs.jmedchem.6b00680
31. [31]
  Y.N. Chen, M.J. LaMarche, H.M. Chan, et al., Nature 535(2016) 148-152. doi: 10.1038/nature18621
32. [32]
  S. De Munter, M. Köhn, M. Bollen, ACS Chem. Biol. 8(2013) 36-45. doi: 10.1021/cb300597g
33. [33]
  M. Cargnello, P.P. Roux, Microbiol. Mol. Biol. Rev. 75(2011) 50-83. doi: 10.1128/MMBR.00031-10
34. [34]
  X. Chen, X. Fu, W. Zhao, et al., Signal Transduct. Target. Ther. 5(2020) 83. doi: 10.1038/s41392-020-0192-0
35. [35]
  Z.Q. Shi, D.H. Yu, M. Park, M. Marshall, G.S. Feng, Mol. Cell. Biol. 20(2000) 1526-1536. doi: 10.1128/MCB.20.5.1526-1536.2000
36. [36]
  H. Lu, C. Liu, R. Velazquez, et al., Mol. Cancer Ther. 18(2019) 1323-1334. doi: 10.1158/1535-7163.MCT-18-0852
37. [37]
  L. Santarpia, S.M. Lippman, A.K. El-Naggar, Expert Opin. Ther. Targets 16(2012) 103-119. doi: 10.1517/14728222.2011.645805
38. [38]
  P. Sarver, M. Acker, J.T. Bagdanoff, et al., J. Med. Chem. 62(2019) 1793-1802. doi: 10.1021/acs.jmedchem.8b01726
39. [39]
  J.R. LaRochelle, M. Fodor, V. Vemulapalli, et al., Nat. Commun. 9(2018) 4508. doi: 10.1038/s41467-018-06823-9
40. [40]
  L.M. Francisco, P.T. Sage, A.H. Sharpe, Immunol. Rev. 236(2010) 219-242. doi: 10.1111/j.1600-065X.2010.00923.x
41. [41]
  W.J. Guo, Q. Xu, J. Pharmacol. Sci. 144(2020) 139-146. doi: 10.1016/j.jphs.2020.06.002
42. [42]
  B. Yu, W. Liu, W.M. Yu, et al., Mol. Cancer Ther. 12(2013) 1738-1748. doi: 10.1158/1535-7163.MCT-13-0049-T
43. [43]
  X. Liu, H. Zheng, X. Li, et al., Proc. Natl. Acad. Sci. U. S. A. 113(2016) 984-989. doi: 10.1073/pnas.1508535113
44. [44]
  H. Chen, S. Libring, K.V. Ruddraraju, et al., Oncogene 39(2020) 7166-7180. doi: 10.1038/s41388-020-01488-5
45. [45]
  P. Parsonidis, M. Shaik, A.P. Serafeim, et al., Molecules 24(2019) 4389. doi: 10.3390/molecules24234389
46. [46]
  W.S. Liu, W.Y. Jin, L. Zhou, et al., J. Comput. Aided. Mol. Des. 33(2019) 759-774. doi: 10.1007/s10822-019-00213-z
47. [47]
  J. Xie, X. Si, S. Gu, et al., J. Med. Chem. 60(2017) 10205-10219. doi: 10.1021/acs.jmedchem.7b01520
48. [48]
  C. Chen, T. Xue, P. Fan, et al., Oncol. Lett. 15(2018) 10055-10062.
49. [49]
  Z.Q. Liu, T. Liu, C. Chen, et al., Toxicol. Appl. Pharmacol. 285(2015) 61-70. doi: 10.1016/j.taap.2015.03.011
50. [50]
  B. Lamothe, M. Yamada, U. Schaeper, et al., Mol. Cell. Biol. 24(2004) 5657-5666. doi: 10.1128/MCB.24.13.5657-5666.2004
51. [51]
  G.A. Rodrigues, M. Falasca, Z. Zhang, S.H. Ong, J. Schlessinger, Mol. Cell. Biol. 20(2000) 1448-1459. doi: 10.1128/MCB.20.4.1448-1459.2000
52. [52]
  Y. Ren, S. Meng, L. Mei, et al., J. Biol. Chem. 279(2004) 8497-8505. doi: 10.1074/jbc.M312575200
53. [53]
  R.R. Wang, W.S. Liu, L. Zhou, Y. Ma, R.L. Wang, J. Biomol. Struct. Dyn. 38(2020) 1525-1538. doi: 10.1080/07391102.2019.1613266
54. [54]
  R.J. Nichols, F. Haderk, C. Stahlhut, et al., Nat. Cell. Biol. 20(2018) 1064-1073. doi: 10.1038/s41556-018-0169-1
55. [55]
  J. Gillson, Y. Ramaswamy, G. Singh, et al., Cancers (Basel) 12(2020) 1341. doi: 10.3390/cancers12051341
56. [56]
  X. Zhang, Y. He, S. Liu, et al., J. Med. Chem. 53(2010) 2482-2493. doi: 10.1021/jm901645u
57. [57]
  A.J. Barr, Future Med. Chem. 2(2010) 1563-1576. doi: 10.4155/fmc.10.241
58. [58]
  S. Butterworth, M. Overduin, A.J. Barr, Future Med. Chem. 6(2014) 1423-1437. doi: 10.4155/fmc.14.88
59. [59]
  L.F. Zeng, R.Y. Zhang, Z.H. Yu, et al., J. Med. Chem. 57(2014) 6594-6609. doi: 10.1021/jm5006176
60. [60]
  Q. Wang, W.C. Zhao, X.Q. Fu, Q.C. Zheng, Front. Chemistry 8(2020) 1059.
61. [61]
  R.Y. Zhang, Z.H. Yu, L. Zeng, et al., Oncotarget 7(2016) 73817-73829. doi: 10.18632/oncotarget.12074
62. [62]
  R. Tsutsumi, H. Ran, B.G. Neel, FEBS Open Bio. 8(2018) 1405-1411. doi: 10.1002/2211-5463.12493
63. [63]
  Z.H. Yu, R.Y. Zhang, C.D. Walls, et al., Biochemistry 53(2014) 4136-4151. doi: 10.1021/bi5002695
64. [64]
  Y. Zhao, X. Zhang, K. Guda, et al., Proc. Natl. Acad. Sci. U. S. A. 107(2010) 2592-2597. doi: 10.1073/pnas.0914884107
65. [65]
  H. Luo, C.T. Vong, H. Chen, et al., Chin. Med. 14(2019) 48.
66. [66]
  W. Liu, B. Yu, G. Xu, et al., J. Med. Chem. 56(2013) 7212-7721. doi: 10.1021/jm400474r
67. [67]
  R.J. Chan, M.B. Leedy, V. Munugalavadla, et al., Blood 105(2005) 3737-3742. doi: 10.1182/blood-2004-10-4002
68. [68]
  S. Liu, Z. Han, A.L. Trivett, et al., Cancer Immunol. Immunother. 68(2019) 1059-1071. doi: 10.1007/s00262-019-02326-8
69. [69]
  L. Jin, Z. Wu, Y. Wang, X. Zhao, Chin. Med. 15(2020) 66. doi: 10.1186/s13020-020-00348-4
70. [70]
  C.G. Vazhappilly, E. Saleh, W. Ramadan, et al., Invest. New Drugs 37(2019) 252-261. doi: 10.1007/s10637-018-0626-5
71. [71]
  L. Chen, D. Pernazza, L.M. Scott, et al., Biochem. Pharmacol. 80(2010) 801-810. doi: 10.1016/j.bcp.2010.05.019
72. [72]
  L.M. Scott, H.R. Lawrence, S.M. Sebti, N.J. Lawrence, J. Wu, Curr. Pharm. Des. 16(2010) 1843-1862. doi: 10.2174/138161210791209027
73. [73]
  N. Hanna, A. Montagner, W.H. Lee, et al., FEBS Lett. 580(2006) 2477-2482. doi: 10.1016/j.febslet.2006.03.088
74. [74]
  C. Chen, M. Cao, S. Zhu, et al., Sci. Rep. 5(2015) 17626. doi: 10.1038/srep17626
75. [75]
  K. Hellmuth, S. Grosskopf, C.T. Lum, et al., Proc. Natl. Acad. Sci. U. S. A. 105(2008) 7275-7280. doi: 10.1073/pnas.0710468105
76. [76]
  H.R. Lawrence, R. Pireddu, L. Chen, et al., J. Med. Chem. 51(2008) 4948-4956. doi: 10.1021/jm8002526
77. [77]
  C.K. Qu, Cell Res. 10(2000) 279-288. doi: 10.1038/sj.cr.7290055
78. [78]
  K.P. Rakesh, S.M. Wang, J. Leng, et al., Anticancer Agents Med. Chem. 18(2018) 488-505. doi: 10.2174/1871520617666171103140749
79. [79]
  V.E. Schneeberger, Y. Ren, N. Luetteke, et al., Oncotarget 6(2015) 6191-6202. doi: 10.18632/oncotarget.3356
80. [80]
  A. Tomiyama, T. Kobayashi, K. Mori, K. Ichimura, Cancers (Basel) 11(2019) 241. doi: 10.3390/cancers11020241
81. [81]
  U.A. Germann, B.F. Furey, W. Markland, et al., Mol. Cancer Ther. 16(2017) 2351-2363. doi: 10.1158/1535-7163.MCT-17-0456
82. [82]
  M.J. LaMarche, M. Acker, A. Argintaru, et al., J. Med. Chem. 63(2020) 13578-13594. doi: 10.1021/acs.jmedchem.0c01170
83. [83]
  K.P. Papadopoulos, S.H.I. Ou, M.L. Johnson, et al., J. Clin. Oncol. 37(2019) 3161. doi: 10.1200/JCO.2019.37.15_suppl.TPS3161
84. [84]
  J. Hallin, L.D. Engstrom, L. Hargis, et al., Cancer Discov. 10(2020) 54-71. doi: 10.1158/2159-8290.CD-19-1167
85. [85]
  D. Qian, M. Behera, C.E. Steuer, et al., J. Clin. Oncol. 38(2020) 21079. doi: 10.1200/JCO.2020.38.15_suppl.e21079
86. [86]
  H. Lu, C. Liu, H. Huynh, et al., Oncotarget 11(2020) 265-281. doi: 10.18632/oncotarget.27435
87. [87]
  C. Bredrup, T. Stokowy, J. McGaughran, et al., Eur. J. Hum. Genet. 27(2019) 574-581. doi: 10.1038/s41431-018-0323-z
88. [88]
  A.H. Sharpe, K.E. Pauken, Nat. Rev. Immunol. 18(2018) 153-167. doi: 10.1038/nri.2017.108
89. [89]
  J. Gong, A. Chehrazi-Raffle, S. Reddi, R. Salgia, J. Immunother. Cancer 6(2018) 8. doi: 10.1186/s40425-018-0316-z
90. [90]
  M. Li, R. Schulz, M. Chisholm-Burns, J. Wang, Z.K. Lu, J. Manag. Care Spec. Pharm. 26(2020) 1477-1486.
91. [91]
  C. Kim, B. Kim, Nutrients 10(2018) 1021. doi: 10.3390/nu10081021
92. [92]
  J. Du, J. Guo, D. Kang, et al., Chin. Chem. Lett. 31(2020) 1695-1708. doi: 10.1016/j.cclet.2020.03.028
1. [1]
  Si Ha , Jiacheng Zhu , Hua Xiang , Guoshun Luo . Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: Past, present and future perspectives. Chinese Chemical Letters, 2024, 35(8): 109192-. doi: 10.1016/j.cclet.2023.109192
2. [2]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
3. [3]
  Shangqian Zhang , Jiaxuan Li , Xuan Hu , Zelong Chen , Junliang Dong , Chenhao Hu , Shuang Chao , Yinghua Lv , Yuxin Pei , Zhichao Pei . H₂S and NIR light-driven nanomotors induce disulfidptosis for targeted anticancer therapy by enhancing disruption of tumor metabolic symbiosis. Chinese Chemical Letters, 2025, 36(1): 110314-. doi: 10.1016/j.cclet.2024.110314
4. [4]
  Ling Yang , Min Ren , Jie Wang , Liming He , Shanshan Wu , Shuai Yang , Wei Zhao , Hao Cheng , Xiaoming Zhou , Maling Gou . A non-viral gene therapy for melanoma by staphylococcal enterotoxin A. Chinese Chemical Letters, 2024, 35(5): 108822-. doi: 10.1016/j.cclet.2023.108822
5. [5]
  Zhiyu Yu , Xiang Luo , Cheng Zhang , Xin Lu , Xiaohui Li , Pan Liao , Zhongqiu Liu , Rong Zhang , Shengtao Wang , Zhiqiang Yu , Guochao Liao . Mitochondria-targeted carrier-free nanoparticles based on dihydroartemisinin against hepatocellular carcinoma. Chinese Chemical Letters, 2024, 35(10): 109519-. doi: 10.1016/j.cclet.2024.109519
6. [6]
  Huamei Zhang , Jingjing Liu , Mingyue Li , Shida Ma , Xucong Zhou , Aixia Meng , Weina Han , Jin Zhou . Imaging polarity changes in pneumonia and lung cancer using a lipid droplet-targeted near-infrared fluorescent probe. Chinese Chemical Letters, 2024, 35(12): 110020-. doi: 10.1016/j.cclet.2024.110020
7. [7]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
8. [8]
  Ke Gong , Jinghan Liao , Jiangtao Lin , Quan Wang , Zhihua Wu , Liting Wang , Jiali Zhang , Yi Dong , Yourong Duan , Jianhua Chen . Mitochondria-targeted nanoparticles overcome chemoresistance via downregulating BACH1/CD47 axis in ovarian carcinoma. Chinese Chemical Letters, 2024, 35(5): 108888-. doi: 10.1016/j.cclet.2023.108888
9. [9]
  Jinyu Guo , Yandai Lin , Shaohua He , Yueqing Chen , Fenglu Li , Renjie Ruan , Gaoxing Pan , Hexin Nan , Jibin Song , Jin Zhang . Utilizing dual-responsive iridium(Ⅲ) complex for hepatocellular carcinoma: Integrating photoacoustic imaging with chemotherapy and photodynamic therapy. Chinese Chemical Letters, 2024, 35(9): 109537-. doi: 10.1016/j.cclet.2024.109537
10. [10]
  Xiaoshuai Wu , Bailei Wang , Yichen Li , Xiaoxuan Guan , Mingjing Yin , Wenquan Lv , Yin Chen , Fei Lu , Tao Qin , Huyang Gao , Weiqian Jin , Yifu Huang , Cuiping Li , Ming Gao , Junyu Lu . NIR driven catalytic enhanced acute lung injury therapy by using polydopamine@Co nanozyme via scavenging ROS. Chinese Chemical Letters, 2025, 36(2): 110211-. doi: 10.1016/j.cclet.2024.110211
11. [11]
  Chao Zhang , Ai-Feng Liu , Shihui Li , Fang-Yuan Chen , Jun-Tao Zhang , Fang-Xing Zeng , Hui-Chuan Feng , Ping Wang , Wen-Chao Geng , Chuan-Rui Ma , Dong-Sheng Guo . A supramolecular formulation of icariin@sulfonatoazocalixarene for hypoxia-targeted osteoarthritis therapy. Chinese Chemical Letters, 2025, 36(1): 109752-. doi: 10.1016/j.cclet.2024.109752
12. [12]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
13. [13]
  Kun Zhang , Ni Dan , Dan-Dan Ren , Ruo-Yu Zhang , Xiaoyan Lu , Ya-Pan Wu , Li-Lei Zhang , Hong-Ru Fu , Dong-Sheng Li . A small D-A molecule with highly heat-resisting room temperature phosphorescence for white emission and anti-counterfeiting. Chinese Journal of Structural Chemistry, 2024, 43(3): 100244-100244. doi: 10.1016/j.cjsc.2024.100244
14. [14]
  Aolei Tan , Xiaoxiao Ma . Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics. Chinese Chemical Letters, 2024, 35(8): 109276-. doi: 10.1016/j.cclet.2023.109276
15. [15]
  Hao Cai , Xiaoyan Wu , Lei Jiang , Feng Yu , Yuxiang Yang , Yan Li , Xian Zhang , Jian Liu , Zijian Li , Hong Bi . Lysosome-targeted carbon dots with a light-controlled nitric oxide releasing property for enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(4): 108946-. doi: 10.1016/j.cclet.2023.108946
16. [16]
  Brandon Bishop , Shaofeng Huang , Hongxuan Chen , Haijia Yu , Hai Long , Jingshi Shen , Wei Zhang . Artificial transmembrane channel constructed from shape-persistent covalent organic molecular cages capable of ion and small molecule transport. Chinese Chemical Letters, 2024, 35(11): 109966-. doi: 10.1016/j.cclet.2024.109966
17. [17]
  Yunjie Dang , Yanru Feng , Xiao Chen , Chaoxing He , Shujie Wei , Dingyang Liu , Jinlong Qi , Huaxing Zhang , Shaokun Yang , Zhiyun Niu , Bai Xiang . Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and small-molecule drugs in tumor treatment. Chinese Chemical Letters, 2024, 35(12): 109660-. doi: 10.1016/j.cclet.2024.109660
18. [18]
  Yunkang Tong , Haiqiao Huang , Haolan Li , Mingle Li , Wen Sun , Jianjun Du , Jiangli Fan , Lei Wang , Bin Liu , Xiaoqiang Chen , Xiaojun Peng . Cooperative bond scission by HRP/H₂O₂ for targeted prodrug activation. Chinese Chemical Letters, 2024, 35(12): 109663-. doi: 10.1016/j.cclet.2024.109663
19. [19]
  Bin Fang , Jiaqi Yang , Limin Wang , Haoqin Li , Jiaying Guo , Jiaxin Zhang , Qingyuan Guo , Bo Peng , Kedi Liu , Miaomiao Xi , Hua Bai , Li Fu , Lin Li . A mitochondria-targeted H₂S-activatable fluorogenic probe for tracking hepatic ischemia-reperfusion injury. Chinese Chemical Letters, 2024, 35(6): 108913-. doi: 10.1016/j.cclet.2023.108913
20. [20]
  Jia Chen , Yun Liu , Zerong Long , Yan Li , Hongdeng Qiu . Colorimetric detection of α-glucosidase activity using Ni-CeO₂ nanorods and its application to potential natural inhibitor screening. Chinese Chemical Letters, 2024, 35(9): 109463-. doi: 10.1016/j.cclet.2023.109463

Get Citation

PDF

XML

Metrics

PDF Downloads(34)
Abstract views(1437)
HTML views(259)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142